| Active substance | amivantamab |
| Holder | Janssen-Cilag |
| Status | Running |
| Indication | treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins), and whose disease has progressed during or after current standard of care platinum-based chemotherapy. |
| Public documents | Approbation |
| Approbation - Amendment | |
| Information for the patient | |
| Information for the patient - amendment | |
| Informed Consent | |
| Informed Consent - amendment | |
| Last update |
04/04/2023 |